Intellia therapeutics inc
NTLA 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面獲得最高評分，但股利評分未超過2分，若公司開始配息，可能會有更優異的投資結果
NTLA 近期報酬表現
-5.43%
Intellia therapeutics inc
0.54%
同產業平均
-0.46%
S&P500
與 NTLA 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
BEAM | Beam therapeutics inc | 3 分 | 2 分 | 1 分 | 3 分 | 1 分 | |
EDIT | Editas medicine inc | 2 分 | 1 分 | 2 分 | 1 分 | 1 分 | |
DNLI | Denali therapeutics inc | 4 分 | 1 分 | 2 分 | 3 分 | 1 分 | |
ALEC | Alector inc | 3 分 | 1 分 | 2 分 | 3 分 | 1 分 | |
VERV | Verve therapeutics inc | - | 1 分 | 1 分 | 3 分 | 1 分 |
- BEAM Beam therapeutics inc價值 3 分趨勢 2 分波段 1 分籌碼 3 分股利 1 分查看更多
NTLA 公司資訊
Intellia Therapeutics, Inc. is a clinical-stage genome editing company, which is focused on developing curative therapeutics using Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) technology. CRISPR/Cas9 is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid. It is focused on leveraging its modular platform to advance in vivo and ex vivo therapies for diseases with high unmet need. Its lead in vivo candidate, NTLA-2001, is for the treatment of transthyretin (ATTR) amyloidosis, as well as NTLA-2002 for the treatment of hereditary angioedema (HAE) are the first CRISPR/Cas9-based therapy candidates to be administered systemically, via intravenous (IV) infusion, for precision editing of a gene in a target tissue in humans. It is also developing ex vivo applications to address immuno-oncology and autoimmune diseases.